Acumen Pharmaceuticals Inc

NASDAQ ABOS

Data sourced from iex and EODHD
Download Data

Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the quarter ending March 31, 2024

Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the quarter ending March 31, 2024. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -10,967,874.50, a -20.64% change year over year.
  • Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -9,091,662.61, a -125.17% change year over year.
  • Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2021 was 36,118,984.48, a 1,866.21% change year over year.
  • Acumen Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2020 was -2,044,999.51.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email